Nouvelle déclaration d'incident
No de la demande: 2020-5445
Numéro de référence du titulaire d'homologation: USA-BAYERBAH-2020-US0047414 (Report 664563)
Nom du titulaire (nom légal complet, aucune abbréviation): Elanco
Adresse: 150 Research Lane, Suite 120
Ville: Guelph
État: ON
Pays: Canada
Code postal /Zip: N1G 4T2
Incident chez un animal domestique
Pays: UNITED STATES
État: INDIANA
Inconnu
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. Inconnu
Nom du produit: K9 Advantix II pipette size unknown
Autre (préciser)
Spot-onOui
Inconnu
Site: Animal / Usage sur un animal domestique
Inconnu
Autre
Dog / Chien
Chihuahua
1
Femme
11
Inconnu
Cutanée
Unknown / Inconnu
Unknown / Inconnu
Système
Unknown / Inconnu
Non
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On an unspecified date in approximately 2015, approximately 1 day post application, the dog exhibited twitching, generalized erythema, hyperactivity, generalized pruritus, and skin warmth. On an unspecified date post application in approximately 2015, post application, the clinical signs resolved. The dog was not examined by a veterinarian and no known treatments were performed. On an unspecified date post application in approximately 2015, the dog exhibited 1 seizure and then died. No necropsy was performed. No more information is expected and this case is closed.
Mort
O - Unclassifiable/unassessable Although usually pruritus is limited to the application site, reported twitching, generalized pruritus and hyperactivity may reflect permethrin-induced paresthesia and/or be a consequence of the feeling caused by the applied product. Skin disorders like generalized erythema and skin warmth on other sites than the application site are not typically seen. If any, signs would be localized at the application site. However, considering short time to onset, signs may represent a sensitivity reaction to the product. Pruritus may have triggered or exaggerated other reported signs. Although product (containing a type I pyrethroid) may cause mild transient neurological signs, later reported seizure is not expected following product use. Secondly, dermal absorption is minimal. Other causes should be considered, e.g. idiopathic epilepsy, trauma, neoplasm. Unclear if seizures were confirmed by veterinarian. Thus, misinterpretation of clinical sign cannot be ruled out. Other unrelated causes are more probable in this geriatric dog with unknown health condition. Death after product application is not expected in dogs either, as it is inconsistent with the pharmaco-toxicological profile of the product. Time to onset is more than 12 hours, therefore an allergic/anaphylactic-type reaction can be ruled out. Time to onset is unknown, however supposedly long. Furthermore, time taken for reporting is long (5 years) as reporting of this adverse event likely done during the report of linked recent adverse event in another dog with same product. Overall, a product relation is considered unassessable.